Skip to content

Kyverna Therapeutics, Inc. KYTX Comprehensive Income (Loss), Net of Tax, Attributable to Parent

Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies

Climb Bio, Inc. logo
Climb Bio, Inc.CLYM
-$14M+31.8%
Artiva Biotherapeutics, Inc. logo
Artiva Biotherapeutics, Inc.ARTV
-$23.64M-17.1%
Viridian Therapeutics, Inc. logo
Viridian Therapeutics, Inc.VRDN
-$105.91M-22.2%
Vor Biopharma logo
Vor BiopharmaVOR
-$220.33M-578%
Allogene Therapeutics logo
Allogene TherapeuticsALLO
-$43.06M+27.8%
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
-$18.26M-178%

Other financials

Income statement

See full
Operating income-$41.4M+12.7%
Net income-$39.7M+11.0%
EPS (diluted)-$0.66+35.9%

Balance sheet

See full
Cash & equivalents$32.2M-43.4%
Total debt$9.2M+32.1%
Total equity$195.6M-12.7%
Total assets$257.0M-1.4%

Cash flow

See full
Operating cash flow-$41.6M+7.4%
CapEx$2.0K-98.0%
Free cash flow-$33.5M+10.8%

Valuation

See full
Market cap$498.52M+276%
Enterprise value$475.49M+475%

Returns & leverage

See full
Return on equity-74.5%+74.4pp
Debt / equity0.0×
Current ratio8.1×+0.7×

Where this comes from

Reported directly by Kyverna Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.

The official record: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kyverna Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kyverna Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent?
Kyverna Therapeutics, Inc. (KYTX) reported comprehensive income (loss), net of tax, attributable to parent of -$39.92M in Q1 2026.
How has Kyverna Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
Kyverna Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent increased by 10.8% year-over-year, from -$44.74M to -$39.92M.
What is the long-term trend for Kyverna Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent?
Over 2 years (2023 to 2025), Kyverna Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent has grown at a 63.5% compound annual growth rate (CAGR), from -$60.34M to -$161.32M.
What does comprehensive income (loss), net of tax, attributable to parent mean?
This metric measures the total change in equity resulting from all non-owner sources, including net income and other comprehensive income items such as unrealized gains or losses on securities. It provides a more holistic view of the company's financial performance by accounting for items that bypass the traditional net income calculation. It is essential for assessing the total impact of market and economic conditions on the company's overall financial position.